Plasma Cell Dyscrasias

What are Plasma Cell Dyscrasias?
Plasma cell dyscrasias (also called plasma cell disorders) refer to a group of conditions where abnormal plasma cells, a type of white blood cell responsible for producing antibodies, grow uncontrollably. Plasma cells are a normal part of the immune system and are produced in the bone marrow to help fight infections by producing antibodies (immunoglobulins). In plasma cell dyscrasias, these cells become abnormal and proliferate, often producing abnormal antibodies. The most well-known plasma cell dyscrasia is multiple myeloma, but this group also includes monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma, and Waldenström’s macroglobulinemia.

Types of Plasma Cell Dyscrasias
  • Multiple Myeloma (MM): The most common and aggressive plasma cell dyscrasia. It is a cancer of plasma cells in the bone marrow that causes uncontrolled growth of malignant plasma cells and production of monoclonal proteins (M-proteins). These abnormal cells crowd out normal blood cells, leading to anaemia, bone pain, infections, bleeding, kidney damage, and renal failure due to light chain deposition.

    Symptoms of multiple myeloma:
    • Bone pain (especially back, ribs, hips)
    • Anaemia (fatigue, pallor)
    • Frequent infections
    • Kidney dysfunction
    • Hypercalcemia
    • Nerve damage (advanced disease)
  • Monoclonal Gammopathy of Undetermined Significance (MGUS): A condition marked by the presence of monoclonal protein in the blood without symptoms or organ damage. MGUS is considered a precursor to multiple myeloma, though only about 1% of patients per year progress to a more serious condition.

    Diagnosis:
    • Blood tests showing elevated M-protein without organ damage
  • Smouldering Multiple Myeloma: An intermediate stage between MGUS and active multiple myeloma, characterised by monoclonal proteins and increased plasma cells in the bone marrow, but without significant symptoms or organ damage. Requires close monitoring due to risk of progression.

    Symptoms:
    • Typically asymptomatic
  • Waldenström’s Macroglobulinemia: A rare lymphoma involving abnormal B cells and plasma cells that produce monoclonal IgM antibodies. High IgM levels can cause hyperviscosity syndrome.

    Symptoms:
    • Fatigue
    • Bleeding or easy bruising
    • Numbness or weakness
    • Vision problems
    • Swollen lymph nodes or enlarged spleen
    • Hyperviscosity symptoms (blurred vision, headaches, dizziness, confusion)
Pathophysiology

Plasma cell dyscrasias arise from a genetic mutation or clonal expansion of a single plasma cell that divides uncontrollably, producing excessive monoclonal proteins.

  • Bone marrow suppression: Leads to anaemia, thrombocytopenia, and neutropenia.
  • Organ damage: Kidney, nerve, and immune system impairment.
  • Bone damage: Osteolytic lesions in multiple myeloma causing fractures and pain.
Diagnosis
  • Blood tests: SPEP or immunofixation to detect M-proteins
  • Urine tests: Detection of Bence-Jones proteins (light chains)
  • Complete blood count (CBC): Identifies anaemia or cytopenias
  • Beta-2-microglobulin: Assesses prognosis in multiple myeloma
  • Bone marrow biopsy: Determines plasma cell burden and abnormalities
  • Imaging: X-rays, CT, or MRI to detect bone lesions or lymphadenopathy
  • Genetic testing: Identifies high-risk cytogenetic abnormalities
Treatment

Treatment depends on the specific plasma cell dyscrasia and disease activity.

  • Multiple Myeloma:
    • Chemotherapy (e.g., melphalan, cyclophosphamide, bortezomib)
    • Immunotherapy (e.g., daratumumab)
    • Autologous stem cell transplant
    • Bone-targeted therapy (bisphosphonates, denosumab)
  • MGUS: No treatment required; regular monitoring only
  • Smouldering Myeloma: Observation and close follow-up
  • Waldenström’s Macroglobulinemia: Chemotherapy, immunotherapy (e.g., rituximab), and plasma exchange for hyperviscosity
Prognosis
  • Multiple myeloma: Median survival 5–10 years with modern therapies
  • MGUS: Very low progression risk; often lifelong without symptoms
  • Waldenström’s macroglobulinemia: Chronic but manageable condition
Summary: Plasma cell dyscrasias are disorders of abnormal plasma cell growth and monoclonal antibody production. They include multiple myeloma, MGUS, smouldering myeloma, and Waldenström’s macroglobulinemia. Diagnosis relies on blood tests, bone marrow biopsy, and imaging, while treatment ranges from monitoring to chemotherapy, immunotherapy, and stem cell transplantation.
Support Our Work

Your donation helps support education, awareness, and care for people living with plasma cell disorders.

Donate to Support Plasma Cell Disorder Care